CD19 and age-related macular degeneration: Conversely, 6 immune cell features may mitigate the risk of AMD: TD CD4+ %T cell (OR = 0.831, 95% CI 0.700–0.987, p = 0.034), CD4RA on TD CD4+ (OR = 0.910, 95% CI 0.852–0.972, p = 0.005), CD19 on IgD− CD38dim (OR = 0.911, 95% CI 0.834–0.995, p = 0.039), Activated & resting Treg % CD4 Treg (OR = 0.928, 95% CI 0.888–0.970, p < 0.001), CD45RA on resting Treg (OR = 0.940, 95% CI 0.899–0.984, p = 0.007), CD39+ resting Treg % CD4 Treg (OR = 0.963, 95% CI 0.937–0.989, p = 0.006).